Search Results
Your search for can matches 13758 pages
Showing 7451 - 7500Presurgical Targeted Therapy Delays Relapse of High-Risk Stage III Melanoma
A pair of targeted therapies given before and after surgery for melanoma produced at least a sixfold increase in time to progression compared to standard-of-care surgery for patients with stage III disease, Amaria et al reported in The Lancet Oncology. Patients who had no sign of disease at surgery ...
ECHELON-1: A Commendable Study, but Questions Remain
“The important thing is not to stop questioning. Curiosity has its own reason for existing.” —Albert Einstein The phase III international ECHELON-1 study, designed to evaluate brentuximab vedotin (Adcetris) as part of a front-line chemotherapy regimen for previously untreated advanced classic...
Tumor-Specific T Cells and Response in Relapsed Hodgkin Lymphoma
In a study reported in the Journal of Clinical Oncology, Bollard et al found that T cells with forced expression of dominant-negative transforming growth factor-β (TGF-β) receptor type 2 (DNRII) that targeted the Epstein Barr virus (EBV)-derived tumor antigens latent membrane proteins...
2018 GI CANCERS SYMPOSIUM: Liquid Biopsy Test May Detect Early-Stage Colorectal Cancer
A new study has found that a test that identifies circulating tumor cells (CTCs) present in the bloodstream can detect colorectal cancer at an early stage, with accuracy ranging from 84% to 88%. Most prior studies using CTCs have been able to detect late-stage colorectal cancer, and this study is...
Estrogen-Mimicking Compounds Found in Many Foods May Reduce Effectiveness of Breast Cancer Treatment
Scientists from The Scripps Research Institute (TSRI) have found that two estrogen-mimicking compounds found in many foods appear to potently reverse the effects of palbociclib/letrozole, a popular drug combination for treating breast cancer. The study, published by Warth et al in Cell Chemical...
CAP Guideline Details HPV Testing in Head and Neck Carcinomas
Patients with certain head and neck cancers who test positive for high-risk types of human papillomavirus (HPV) have a better prognosis and may need less aggressive treatment. To help ensure that patients with these cancers are accurately diagnosed and effectively treated, the College of...
Brentuximab Vedotin Plus Bendamustine in Relapsed/Refractory Hodgkin Lymphoma
A phase I/II trial has shown that the addition of brentuximab vedotin (Adcetris) to bendamustine is active in relapsed or refractory Hodgkin lymphoma. Study findings were reported in The Lancet Oncology by O’Connor et al. Study Details In the study, 64 patients with Hodgkin lymphoma and 1...
Study Finds Desmoplastic Melanoma Highly Responsive to PD-1/PD-L1 Blockade
Desmoplastic melanoma is a rare subtype of melanoma that is commonly found on sun-exposed areas, such as the head and neck, and usually seen in older patients. Treatment is difficult, as these tumors are often resistant to chemotherapy and lack actionable mutations commonly found in other types of...
Study Finds Gene-Expression Profile Testing for Breast Cancer Less Cost-Effective in Real-World Practice
The most commonly used gene expression profile test used to help predict breast cancer recurrence may not be as cost-effective as once thought, say a team of researchers led by scientists from Georgetown Lombardi Comprehensive Cancer Center. Their study, published by Chandler et al in the Journal...
Durable Complete Responses After Discontinuation of Immunotherapy in Metastatic Melanoma
As reported in the Journal of Clinical Oncology by Robert and colleagues, a high proportion of patients with metastatic melanoma achieving complete response on pembrolizumab (Keytruda) in the phase Ib KEYNOTE-001 trial maintained complete response for prolonged durations after treatment...
Growing Socioeconomic and Racial Disparities in Management of Brain Metastases
Increasing use of a potentially life-saving treatment for metastatic cancer is leaving too many vulnerable patients behind, according to a new study from Yale Cancer Center/Smilow Cancer Hospital published by Kann et al in JNCCN – Journal of the National Comprehensive Cancer Network. The...
Bipolar Androgen Therapy After Progression on Enzalutamide in Metastatic Castration-Resistant Prostate Cancer
In a single-center phase II study reported in The Lancet Oncology, Teply et al found that bipolar androgen therapy can induce prostate-specific antigen (PSA) response and resensitization to enzalutamide (Xtandi) in men with metastatic castration-resistant prostate cancer who progressed on...
New Cancer Model Shows Genomic Link Between DCIS and IDC Breast Cancer Types
A new genetic-based model may explain how ductal carcinoma in situ (DCIS) progresses to a more invasive form of cancer, say researchers at The University of Texas MD Anderson Cancer Center. The study provides new insight into how DCIS leads to invasive ductal carcinoma (IDC) and provides a clearer...
Treatment With Carfilzomib May Lead to Cardiovascular Toxicity in Patients With Multiple Myeloma
The proteasome inhibitor carfilzomib (Kyprolis) has taken on an increasing role in the treatment of multiple myeloma, but new research from the Abramson Cancer Center of the University of Pennsylvania shows the therapy may come with the risk of cardiovascular problems in a higher than expected...
Oncology World Mourns the Loss of Jimmie C. Holland, MD, Founder, Field of Psycho-Oncology
Jimmie C. Holland, MD, died suddenly on December 24, 2017, at the age of 89 years. Dr. Holland was the Attending Psychiatrist and Wayne E. Chapman Chair at Memorial Sloan Kettering (MSK) Cancer Center and Professor of Psychiatry, Weill Medical College of Cornell University in New York....
Harborside Partners With MAZ to Launch OncologyGo, Cancer Resource for Mobile Devices and TV
Media technology company, MAZ, has partnered with Harborside, a medical communications company based in Huntington, New York, to launch OncologyGo, a streaming-event coverage and video content app for specialists in oncology health care available on Apple TV, Roku, FireTV, and iOS. Harborside...
Is Medical Assistance in Dying Compassionate Care?
Suicidal ideation while receiving end-of-life cancer care is not unusual but can often be reversed by palliative and psychosocial oncology interventions. That said, there are patients who, even after intensive interventions, request medical assistance in dying. Physician-assisted death has been a...
Lower Dose of Cabazitaxel in Prostate Cancer
On September 14, 2017, the microtubule inhibitor cabazitaxel (Jevtana) was approved at the lower dose of 20 mg/m2 every 3 weeks in combination with prednisone for treatment of patients with metastatic castration-resistant prostate cancer previously treated with a docetaxel-containing regimen.1,2...
Alcohol and Cancer Risk Reconsidered
Having valued communications from ASCO since its birth, I was disappointed by the Society’s position on alcohol consumption and cancer risk, as published in a recent issue of the Journal of Clinical Oncology (JCO)1 and summarized in the November 25 issue of The ASCO Post. The statement seems to me ...
Helping Patients With Head and Neck Cancer and Their Caregivers Face Treatment-Associated Challenges
Head and neck cancer remains one of the most challenging clinical presentations faced by the oncology community. Patients must not only face a potentially lethal disease, but must also cope with treatments that often result in significant side effects. To gain a better understanding on the...
Expect Questions About Link Between Alcohol and Cancer
With headlines such as “Cutting back on alcohol can prevent cancers”1 and “Even light drinking may raise your cancer risk,”2 media reports may be generating questions from patients about the ASCO statement summarizing evidence linking alcohol to an increased risk of cancer.3 “What I personally...
Oncologists Urged to Be Proactive in Advising Patients to Reduce Risk of Alcohol-Related Cancers
A recently released ASCO statement summarizing extensive evidence linking alcohol use to an increased risk of several leading cancers, including breast, colon, and head and neck, called on oncologists “as front-line providers for cancer patients” to help patients reduce excessive alcohol use.1...
Assuming the Role of NCI Director: Working to Accelerate Progress
I’m not sure anything can prepare a person to become director of the National Cancer Institute (NCI), but I can honestly say that I am humbled to have been appointed to this position and am excited to have this unique opportunity. As many of you may know, I come to NCI from the University of...
Giving Back After Cancer
My diagnosis of neuroblastoma when I was 14 happened rather accidentally. I was a competitive dancer and very active in sports my first year in high school and had no symptoms of cancer or any illness. It wasn’t until my mother, who is a nurse, came into my room one morning to wake me for school...
Medical Oncologist Takes the Paths Less Traveled to Unwind and Reboot
GUEST EDITOR Dr. Abraham is the Director of the Breast Oncology Program at Taussig Cancer Institute, and Professor of Medicine, Lerner College of Medicine, Cleveland Clinic. For this installment in the Living a Full Life series of articles, Andrew D. Seidman, MD, of Memorial Sloan Kettering Cancer ...
American Association for the Advancement of Science Inducts New Fellows
The American Association for the Advancement of Science (AAAS) has recently inducted 396 members as fellows, with 21 members having oncology backgrounds. Members have been awarded this honor because of their scientifically or socially distinguished efforts to advance science or its applications....
FCC, NCI Working to Improve Rural Cancer Care via Broadband Access
The Connect2Health Task Force, an initiative of the Federal Communmications Commission (FCC), has announced that the FCC and the National Cancer Institute (NCI) have joined forces, signing a memorandum of understanding that will focus on how increasing broadband access and adoption in rural areas...
The Puzzle Table
The ASCO Post is pleased to reproduce installments of the “Art of Oncology” as published previously in the Journal of Clinical Oncology. These articles focus on the experience of suffering from cancer or of caring for people diagnosed with cancer, and they include narratives, topical essays,...
Alectinib in ALK-Positive Metastatic Non–Small Cell Lung Cancer
On November 6, 2017, alectinib (Alecensa) received regular approval for treatment of patients with anaplastic lymphoma kinase (ALK)-positive metastatic non–small cell lung cancer (NSCLC), as detected by a U.S. Food and Drug Administration–approved test.1,2 Supporting Efficacy Data Approval was...
Data Must Be Generated to Support Cross-Labeling of Combination Therapies for Cancer
Combinations of targeted therapies (triple, quadruple, or even more) are part of the future of cancer treatment, which means that traditional clinical trials will have to be streamlined and updated to enable greater flexibility and to extract adequate safety and efficacy data. Problems inherent in...
FDA Helps Streamline Approval Process for Supplemental Drug Indications
As researchers learn more about the natural history of cancers, as more drugs are effective for more types of the disease, and as the number and complexity of combination therapies increase, the more important it is that new drugs and permutations of old ones be available to patients. The U.S. Food ...
WHAT SHOULD PUMA DO?
Puma should invest in developing an escalating-dose schedule for neratinib (Nerlynx). If one plans on giving a drug for a year, and starts after finishing a year of effective adjuvant therapy, there is no hurry to begin at full, intolerable doses. Starting at a lower dose and escalating slowly as...
Neratinib Is Approved: Should We Reject It Anyway?
The U.S. Food and Drug Administration (FDA) approved 1 year of extended adjuvant neratinib (Nerlynx) after chemotherapy and a year of trastuzumab (Herceptin) for HER2-positive breast cancer this summer on the basis of the ExteNET trial. Many were surprised at the approval, since the evidence of...
Providing a Safe Haven for Patients With Advanced Lung Cancer
In 1996, Jimmie C. Holland, MD, the Wayne E. Chapman Chair in Psychiatric Oncology at Memorial Sloan Kettering Cancer Center (MSK) in New York, decided to launch the cancer center’s Lung Cancer Survivorship Program after she had a startling encounter with a patient. “The woman said to me, ‘Would...
St. John’s Wort
The ASCO Post’s Integrative Oncology series is intended to facilitate the availability of evidence-based information on integrative and complementary therapies commonly used by patients with cancer. In this installment, Jun J. Mao, MD, MSCE, and Jyothirmai Gubili, MS, explore the role of St....
Katherine E. Reeder-Hayes, MD, Sees Equity as Next Big Challenge in Breast Cancer Care
Breast cancer specialist Katherine E. Reeder-Hayes, MD, MBA, was born on a farm in Morgan County, Alabama. “My family grew soybeans and cotton and raised cattle. None of my family members were in the medical field, but I always felt comfortable around people who were sick or had emergencies and...
Slovenia’s First Medical Oncology Resident Reflects on His Career in a Rapidly Changing Field
Bostjan Seruga, MD, PhD, is a medical oncology consultant at the Insitute of Oncology Ljubljana and Associate Professor at the University of Ljubljana, Slovenia. He has published on barriers in global cancer research. The ASCO Post spoke with him recently about his career path, cancer care in...
Fulvestrant Monotherapy for Postmenopausal Women With Advanced Breast Cancer
On August 28, 2017, fulvestrant (Faslodex) was approved at 500 mg as monotherapy for expanded use in postmenopausal women with hormone receptor–positive, HER2-negative advanced breast cancer who have not received previous endocrine therapy.1 Supporting Efficacy Data Approval was based on improved...
A Letter of Thanks From the Conquer Cancer Foundation
Small victories matter when you are conquering cancer. Listen to a patient’s loved one detail the progress of treatment. You will hear the value they give to accomplishments that otherwise seem minor: She rested well last night. He managed to eat. The scan showed no new growth! It is easy,...
NIH Research Program Partners With National Library of Medicine to Advance Precision Medicine
THE NATIONAL INSTITUTES OF HEALTH’S All of Us Research Program and the National Library of Medicine (NLM) have teamed up to raise awareness about the program, a landmark effort to advance precision medicine. Through this 3-year pilot program, the National Network of Libraries of Medicine has...
ASCO Kicks Off Strategic Planning to Support Women in Oncology
Women in oncology aren’t ascending the leadership ladder at rates anywhere close to their male counterparts—and ASCO wants to fix that. The most recent report on “The State of Women in Academic Medicine” from the Association of American Medical Colleges (AAMC) said that although women make up...
Another PI3K Inhibitor Welcome For Use in Indolent Lymphoma
PHOSPHATIDYLINOSITOL 3-KINASE (PI3K) signaling is important for the proliferation and survival of malignant B cells. Copanlisib (Aliqopa) is a novel pan-class PI3K inhibitor with predominant activity against PI3K-alpha and PI3K-delta isoforms. As reviewed in this issue of The ASCO Post, a phase II ...
Conquer Cancer Researcher Spotlight: Dr. Xiuning Le
Xiuning Le, MD, PhD Assistant Professor The University of Texas MD Anderson Cancer CenterSpecialty: Thoracic/head & neck cancer, breast cancer Of all the adjectives used to describe cancer, one in particular can be surprising: smart. In fact, one of the reasons cancer can be so hard to treat...
Deadline Approaching: Give a Year-End Gift by December 31
The New Year is almost here—and what better way to close out 2017 than by donating to Conquer Cancer, ASCO’s affiliate organization? Your tax-deductible year-end gift will help fuel advances in prevention, treatment, and cures for all types of cancer. Give now at CONQUER.ORG/Year-End to end 2017...
ASCO Resolutions Approved by AMA House of Delegates
From November 11–14, ASCO delegates participated in the American Medical Association’s (AMA) Interim Meeting of the House of Delegates (HOD), the principal policy-making body of the AMA. During the meeting, several ASCO-backed resolutions were approved, including: Medicare Part B Drugs in QPP/MIPS...
European Union Expert Group Releases Position Statement on Lung Cancer Screening in Europe
AS REPORTED in The Lancet Oncology by Matthijs Oudkerk, MD, of the University of Groningen, the Netherlands, and colleagues, a European Union (EU) expert group has issued a position statement on low-dose computed tomography (CT) screening for lung cancer, proposing a near-term phased implementation ...
Exercise Counteracts Fatigue, Pain in Women With Advanced Breast Cancer
A SUPERVISED and individualized exercise program can reduce fatigue and pain while improving cardiovascular health and quality of life in women being treated for advanced breast cancer, according to research presented by Eduardo Oliveira, PhD, Professor of Exercise Physiology and Exercise Cancer...
Broadening the Evidence Base for Older Patients: FDA-ASCO Workshop Explores Emerging Strategies
In the not-so-distant past, clinical trials were considered an option only for the young and fit. Enrolling older people “used to be thought unethical,” said Janet Woodcock, MD, Director of the U.S. Food and Drug Administration (FDA)’s Center for Drug Evaluation and Research (CDER), as she opened...
Disease Progression and Deterioration of Health-Related Quality of Life in Advanced Breast Cancer
IN PATIENTS WITH estrogen receptor–positive, HER2-negative advanced or metastatic breast cancer, better quality of life may be prolonged by delaying the progression of the disease, according to an ongoing quality-of-life assessment from the PALOMA-2 study, presented by Nadia Harbeck, MD, PhD, of...
Fiber Is Only One Component in Improving Outcomes in Cancer Survivors
SINCE 2003, every iteration of the American Cancer Society’s Nutrition Guidelines for Cancer Survivors has advocated for a plant-based diet with ample quantities of whole grains, as well as vegetables and fruits.1-3 This recommendation has been based primarily on data that such foods play in...
